Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company specializing in treatments for rare genetic skin diseases, has announced its upcoming participation in the Jones Healthcare and Technology Innovation Conference.
The company's Founder and CEO, Wes Kaupinen, will engage in a fireside chat on Wednesday, April 9, 2025, at 2:00 p.m. PT. The presentation will be accessible through a live webcast on the Events and Presentations section of Palvella's website (www.palvellatx.com), with the replay remaining available for approximately 90 days afterward.
Palvella focuses on developing novel therapies for serious rare genetic skin conditions that currently lack FDA-approved treatments.
Palvella Therapeutics (Nasdaq: PVLA), un'azienda biofarmaceutica in fase clinica specializzata nel trattamento di malattie genetiche rare della pelle, ha annunciato la sua prossima partecipazione alla Jones Healthcare and Technology Innovation Conference.
Il Fondatore e CEO dell'azienda, Wes Kaupinen, parteciperà a una chiacchierata informale mercoledì 9 aprile 2025, alle 14:00 PT. La presentazione sarà accessibile tramite un webcast dal vivo nella sezione Eventi e Presentazioni del sito web di Palvella (www.palvellatx.com), con la registrazione disponibile per circa 90 giorni dopo.
Palvella si concentra sullo sviluppo di terapie innovative per gravi condizioni cutanee genetiche rare che attualmente non hanno trattamenti approvati dalla FDA.
Palvella Therapeutics (Nasdaq: PVLA), una empresa biofarmacéutica en etapa clínica especializada en tratamientos para enfermedades raras de la piel de origen genético, ha anunciado su próxima participación en la Jones Healthcare and Technology Innovation Conference.
El fundador y CEO de la empresa, Wes Kaupinen, participará en una charla informal el miércoles 9 de abril de 2025, a las 14:00 PT. La presentación estará disponible a través de una transmisión en vivo en la sección de Eventos y Presentaciones del sitio web de Palvella (www.palvellatx.com), con la repetición disponible durante aproximadamente 90 días después.
Palvella se centra en desarrollar terapias novedosas para condiciones cutáneas genéticas raras y graves que actualmente carecen de tratamientos aprobados por la FDA.
Palvella Therapeutics (Nasdaq: PVLA)는 희귀 유전 피부 질환 치료를 전문으로 하는 임상 단계의 생명공학 회사로, Jones Healthcare and Technology Innovation Conference에 참여할 예정이라고 발표했습니다.
회사의 창립자이자 CEO인 Wes Kaupinen은 2025년 4월 9일 수요일 오후 2시 PT에 화상 대화에 참여할 것입니다. 발표는 Palvella 웹사이트의 이벤트 및 발표 섹션에서 실시간 웹캐스트를 통해 접근할 수 있으며, 재생은 약 90일 동안 제공됩니다.
Palvella는 현재 FDA 승인 치료제가 없는 심각한 희귀 유전 피부 질환에 대한 새로운 치료법 개발에 집중하고 있습니다.
Palvella Therapeutics (Nasdaq: PVLA), une entreprise biopharmaceutique en phase clinique spécialisée dans les traitements des maladies cutanées génétiques rares, a annoncé sa prochaine participation à la Jones Healthcare and Technology Innovation Conference.
Le fondateur et PDG de l'entreprise, Wes Kaupinen, participera à une discussion informelle le mercredi 9 avril 2025, à 14h00 PT. La présentation sera accessible via un webinaire en direct dans la section Événements et Présentations du site web de Palvella (www.palvellatx.com), avec une rediffusion disponible pendant environ 90 jours après.
Palvella se concentre sur le développement de thérapies novatrices pour des conditions cutanées génétiques rares et graves qui n'ont actuellement pas de traitements approuvés par la FDA.
Palvella Therapeutics (Nasdaq: PVLA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Behandlungen seltener genetischer Hautkrankheiten spezialisiert hat, hat seine bevorstehende Teilnahme an der Jones Healthcare and Technology Innovation Conference angekündigt.
Der Gründer und CEO des Unternehmens, Wes Kaupinen, wird am Mittwoch, den 9. April 2025, um 14:00 Uhr PT an einem Gespräch teilnehmen. Die Präsentation wird über einen Live-Webcast im Bereich Veranstaltungen und Präsentationen auf der Website von Palvella (www.palvellatx.com) zugänglich sein, wobei die Wiederholung etwa 90 Tage lang verfügbar bleibt.
Palvella konzentriert sich auf die Entwicklung neuartiger Therapien für schwerwiegende seltene genetische Hauterkrankungen, für die derzeit keine von der FDA genehmigten Behandlungen verfügbar sind.
- None.
- None.
WAYNE, Pa., April 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025, at 2:00 p.m. PT.
A live webcast of the fireside chat will be available on the Events and Presentations section of Palvella's website at www.palvellatx.com. An archived replay of the webcast will be available for approximately 90 days following the presentation.
About Palvella Therapeutics
Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN
QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any indication.
Contact Information
Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com
Media
Marcy Nanus
Managing Partner, Trilon Advisors, LLC
mnanus@trilonadvisors.com
FAQ
When is Palvella Therapeutics (PVLA) presenting at the Jones Healthcare Conference 2025?
How can investors watch Palvella Therapeutics' (PVLA) Jones Conference presentation?
What is Palvella Therapeutics' (PVLA) main business focus?
Who will represent PVLA at the Jones Healthcare Conference 2025?
